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1025MP-170 Opening the Window of Facilitated Percutaneous 
Coronary Intervention in Acute Infarction: The Role of 
Combined llblllla Inhibition and Thrombolytic Therapy 
Mitchell W. Krucoff , Cynthia L. Green. Per Johanson, Suzanne W. Crater, Matthew T. Pisra Anaelica Msrlini. Diego Ardissino, Annamaria Andreoli, Silvio Ricci, Alessandra 
Roe, Anatoly Langer, Robert P. Giugliano, A. Michael Lincoff. Robert A. Harrington, Eric Rep&to, Alessandro Lombardi, Ospedale Niguarda. Milan, Italy, Ospedale Maggiors, 
J. Topol, Robert M. Califf, Duke University Medical Center, Durham, NC Parma, Italy 
Background: Combined llbllla inhibition and lytic therapy have not shown mortality bsn- 
efit vs. lytics alone. however key trials have not used PCI. Restored infarct artery flow 
prior to PCI might facilitate instrumentation, salvage and outcome. 
Methods: The timing of reperfusion (as minutes from the onset of lytic therapy) based on 
>50% ST-segment recovery analyzed from continuous digital 12-lead monitoring ana- 
lyzed in blinded core laboratory was aggregated over 30 minute intervals for all 654 pts. 
from 4 trials (IMPACT-AMI, PARADIGM, GUSTO-V, INTEGRITI) combining lamifiban, 
sptifibatide and abciximab with lytics (COMBO) vs. standard lytics (STD) in patients with 
acute ST elevation Ml. 
Results: (as % of pts. with ST recovery up to the time interval) 
Time (min) 30 60 90 120 180 240 
COMBO, % 37.4 56.7 72.7 79.5 86.6 69.2 
STD. % 33.6 46.0 63.6 72.9 80.6 66.5 
pvalue .34 .03 .02 .06 .04 .30 
Conclusions: While in large trials combined llbllla inhibition and lytic therapy doss not 
convey mortality benefit as lone medical therapy vs. standard lytic therapy, continuous 
12.lead ST recovery data suggest a significantly accelerated early phase of rsperfusion 
beginning 30-60 minutes from treatment and widening over the first 2-3 hours. This 
potentially opens a temporal and technical “window” of opportunity for PCI instrumenta- 
tion in a more stable patient with better distal vessel visualization, which overall might 
improve myocardial salvage and clinical outcomes as a true facilitated PCI strategy. 
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Enoxaparin Is Superior to Unfractionated tleparin After 
Fibrinolysis in Acute Myocardial Infarction: Meta- 
Analysis of ASSENT-3, HART-II, and ENTIRE-TIMl-23 
Trials 
Peter R. Sinnaeve. Elliott M. Antman. Allan M. Ross, Victor Hasselblad, Frans J. Van de 
Wert. Christopher 8. Granger, Duke Clinical Research Institute, Durham, NC, University 
Hospital Gasthuisberg, Leuven, Belgium 
Background ASSENT-3 found that enoxaparin resulted I” lower rates of death, reMI, 
and refractory ischemia than unfractionatsd heparin (UFH). The HART-II and ENTIRE- 
TIMI 23 trials focused on angiographic endpoints with early angiography in all patients. In 
order to combine all available randomized data of snoxaparin vs. UFH following full-dose 
thrombolysis and to include more patients undergoing early angiography, we performed 
a meta-analysis of these trials. 
Methods and results805 patients in the combined dataset underwent urgent angiogra- 
phy on the day of admission. We focused on death, rsinfarction (reMI), and refractory 
ischsmia at 30 days in all trials, and major bleeding. Me&analysis was performed with a 
random effects model. Results are summarized in Table 1. Patients treated with enox- 
aparin had fewer ischsmic complications than with UFH, as demonstrated by a 20% rela- 
tive risk reduction in the triple endpoint. Death was non-statisbcally significantly 
decreased (OR 0.88, 95%CI 0.68-l .14). 
Conclusion Enoxaparin is superior to UFH I” reducing ischemic complications in 
patients with acute MI treated with fibrinolysis, without substantially increasing major 
bleeding even with frequent use of urgent angiography. 
Table I 
Enoxa~adnvsUFH Dsath/ReMl/ 
Refractory 
lschsmia OR 
(95%CI) 
ASSENT-3 0.81 (0.68-0.95) 
(rl=4078) 
ENTIRE (n=242) 0.38 (0.19-0.79) 
HART-II (n=400) 1.21 (0.70-2.10) 
Total 0.80 (0.68-0.95) 
(n=4717) 
Death/ReMI OR Major bleeding 
(95%CI) OR (95%CI) 
0.86 (0.70-l .05) 1.42 (0.96. 
2.01) 
0.24 (0.09-0.62) 0.76 (0.16- 
4.58) 
1 .OO (0.49-2.06) 1.18 (0.39. 
3.57) 
0.74 (0.51-l .09) 1.34 (0.93. 
1.95) 
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1025MP-172 Coagulation Activation Induced by Fibrinolytic Therapy 
Is Blunted by the Combination of a Low-Dose 
Fibrinolytic and a Platelet Glycoprotein Ilb/llla Inhibitor: 
The GUSTO V Italian Hematologic Substudy 
Background: Fibrinolysis in acute myocardial infarction activates blood coagulation and 
may favour reocclusion or ischemic complications. The aim of the GUSTO V Italian 
Hem&logic Substudy was to compare the effects of full-dose retsplase versus half doss 
rsteplass combined with full doss abciximab on the markers of coagulation activation 
soon after myocardial infarction. 
Methods and results: We measured the plasma lsvsl~ of prothrombin fragment I+2 
(F1+2, a marker of prothrombin sctlvation) and the thrombinlantithrombin complex (TAT, 
a marker of thrombin generation) in 67 patients participating in the GUSTO V study who 
were random&d to receive full-dose rstsplase (34 patients) or the combination of half- 
doss reteplase and full-dose abclximab (33 patients), in addition to hepann. Blood sam- 
ples were obtained at baseline, and after 90 minutes and 24 hours. There was no diffsr- 
snce in the baseline plasma levels of F1+2 or TAT between the two groups. Median 
Fl c2 levels at 90 minutes were significantly lower In the patients receiving combination 
therapy than In those rsceivlng retsplase alone (2.0 vs 3.2 nmol/L; P=O.O06), the median 
Increase being significantly greater in the latter (P=O.O07); the same was true in the case 
of median 90-minute TAT levels (6.7 vs 7.9 rig/L;; P=O.O16), with a significantly higher 
median increase in the patients receiving rstsplass alone (P=O.O05). There was no 
between-group difference in the plasma levels of either F1+2 or TAT after 24 hours. Con- 
clusion: In patients with acute myocardial infarction, the combination of half-dose 
rsteplass and full-dose abciximab blunts the increase in prothrombin activation and 
thiombin generation observed with full-doss retsplase. 
